Monday , December 11 2017
Home / KEEP BUT DO NOT DISPLAY / Facts / Acarbose Improves GLP-1 Effects on Newly Diagnosed Type 2 Patients

Acarbose Improves GLP-1 Effects on Newly Diagnosed Type 2 Patients

The benefits of acarbose on cardiovascular risk may be related to its stimulation of GLP-1 secretion. Blood was drawn from 24 subjects with drug-naïve T2D at 0 and 120 min following a standard mixed meal to measure active GLP-1, NO and NOS. The CIMT was measured prior to and following 24 weeks of acarbose monotherapy. Significantly increased levels of both fasting and postprandial GLP-1 as well as significantly increased NO levels and NOS activity for those patients in whom postprandial GLP-1 levels were increased, were seen after the acarbose monotherapy. Cardiovascular Diabetology. 2013;12(73)